LILAC-TIMI 76 is a randomized, double, blind placebo-controlled phase 3 trial investigating the efficacy and safety of the factor XI inhibitor abelacimab in~1,900 patients with AF deemed unsuitable for anticoagulation therapy.
CONTACT US about LILAC
An Academic Research Organization of Brigham & Women's Hospital and An Affiliate of Harvard Medical School